This week in techniques

Approach	Summary	Licensing status	Publication and contact information
Assays & screens			
RNAi-based signatures for characterizing drug mechanism of action	<p>RNAi-based signatures could help identify the mechanism of action of cancer therapies. In lymphoma cell lines, sensitivity profiling led to RNAi-based signatures that grouped cancer therapies by their mechanism of action. Next steps include looking at additional cell lines to identify an optimal signature for characterizing cancer therapies.</p> <p>SciBX 4(4); doi:10.1038/scibx.2011.116 Published online Jan. 27, 2011</p>	Patent application filed; available for licensing	<p>Jiang, H. <i>et al. Nat. Chem. Biol.</i>; published online Dec. 26, 2010; doi:10.1038/nchembio.503</p> <p>Contact: Michael T. Hemann, Massachusetts Institute of Technology, Cambridge, Mass. e-mail: hemann@mit.edu</p>